TACE综合介入治疗晚期原发性肝癌的临床效果及对患者肝功能影响研究

Clinical Effect of TACE Comprehensive Interventional Therapy for Advanced Primary Liver Cancer and Its Influence on Liver Function in Patients

目的探究肝动脉栓塞化疗(transcatheter hepatic arterial chemoembolization,TACE)综合介入治疗晚期原发性肝癌的临床效果,并分析此种治疗方案对患者肝功能的影响。方法方便选取2019年1月—2021年12月福建省龙岩市第二医院收治的98例晚期原发性肝癌患者为研究对象,以随机信封法分为两组,每组49例。参照组采用单纯TACE治疗,研究组采用TACE综合介入治疗,观察两组患者临床效果(肿瘤缓解率、肿瘤直径、肿瘤标志物甲胎蛋白)、肝功能指标变化、不良反应发生率。结果研究组患者临床总缓解率为93.88%,高于参照组的77.55%,差异有统计学意义(χ^(2)=5.333,P<0.05)。治疗前,两组患者肿瘤直径、甲胎蛋白(AFP)比较,差异无统计学意义(t=0.222、0.298,P>0.05);治疗后,研究组患者肿瘤直径、AFP较参照组低,差异有统计学意义(t=5.429、3.793,P<0.05)。治疗前,两组患者谷草转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBIL)比较,差异无统计学意义(t=0.137、0.515、0.265,P>0.05);治疗后,研究组患者AST、ALT、TBIL较参照组低,差异有统计学意义(t=3.847、4.775、7.721,P<0.05)。治疗期间,研究组不良反应发生率为6.12%,与参照组的4.08%比较,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论对晚期原发性肝癌患者,应用TACE综合介入治疗,可以提升肿瘤控制效果,改善肝功能,且安全性高。

Objective To explore the clinical effect of transcatheter hepatic arterial chemoembolization(TACE)comprehensive interventional treatment of advanced primary liver cancer,and analyze the effect of this treatment on liver function of patients.Methods Ninety-eight patients with advanced primary liver cancer admitted to the Second Hospital of Longyan City,Fujian Province from January 2019 to December 2021 were conveniently selected as the study objects and divided into two groups by random envelope method,with 49 cases in each group.The reference group was treated with TACE alone,and the study group was treated with TACE comprehensive interventional therapy.Clinical effects(tumor remission rate,tumor diameter,tumor marker alpha-fetoprotein),changes in liver function indexes,and incidence of adverse reactions were observed in the two groups.Results The total response rate of the study group was 93.88%,higher than that of the reference group(77.55%),the difference was statistically significant(χ^(2)=5.333,P<0.05).Before treatment,there was no statistically significant difference in tumor diameter and alpha-fetoprotein(AFP)between the two groups(t=0.222,0.298,P>0.05).After treatment,the tumor diameter and AFP in the study group were lower than those in the reference group,and the differences were statistically significant(t=5.429,3.793,P<0.05).Before treatment,there was no statistically significant difference in glutamic oxalic aminotransferase(AST),alanine aminotransferase(ALT)and total bilirubin(TBIL)between the two groups(t=0.137,0.515,0.265,P>0.05).After treatment,the AST,ALT and TBIL in the study group were lower than those in the reference group,and the differences were statistically significant(t=3.847,4.775,7.721,P<0.05).During the treatment period,the incidence of adverse reactions in the study group was 6.12%,compared with 4.08%in the reference group,the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion For advanced primary liver cancer patients,TACE comprehensive interventional therapy can improve tumor control and liver function with high safety.